| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
Concentrated thioridazine (0.01-100 μM; 48 h) treatment decreases NCI-N87 and AGS cell viability [2]. Thioridazine (1-15 μM; 24-48 h) promotes cell death via the mitochondrial pathway and pharyngeal pathways. Thioridazine (15 μM; 24 h) lowers cervical (HeLa, Caski, and C33A) and endometrial [2]. Cancer cell viability (HEC-1-A and KLE) [4]. ;24 h) By interfering with PI3K/Akt, it causes cervical cancer cells to develop in the G1 cell cycle [4]. Development of conjugated Bowman immotile cell lines that are susceptible to thioridazine inhibitors [3].
|
|---|---|
| ln Vivo |
Thioridazine (25 mg/kg; intraperitoneal injection every three days for three weeks) can decrease the amount of pluripotent cell carcinoma (EC) cells within the tumor and increase the survival time of tumor-bearing animals [5].
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: NCI-N87 and AGS Cell Tested Concentrations: 0.01, 0.1, 0.5, 1, 5, 10, 20, 50, 100 μM Incubation Duration: 48 hrs (hours) Experimental Results: demonstrated cytotoxicity in gastric cancer cells . Western Blot Analysis [1] Cell Types: NCI-N87 and AGS cells Tested Concentrations: 1, 5, 10, 15 μM Incubation Duration: 24, 48 hrs (hours) Experimental Results: Downregulation of caspase-9, caspase-8 and caspase-3 precursors. |
| Animal Protocol |
Animal/Disease Models: Nude mice and Rag2KO mice were injected with iPS cells or NT2D1 cells [5]
Doses: 25 mg/kg Administration Doses: 5.0 mg/kg; subcutaneous injection) to reduce oral behavior and selectively prevent repetitive head bobbing [1]. Route of Administration: intraperitoneal (ip) injection every 3 days for 3 weeks. Experimental Results: diminished the number of OCT4-expressing cells in malignant teratocarcinoma and prolonged the survival of tumor-bearing mice. Has no effect on fertility. |
| References |
|
| Additional Infomation |
Thioridazine hydrochloride is a hydrochloride. It has a role as a first generation antipsychotic and a geroprotector. It contains a thioridazine.
Thioridazine Hydrochloride is the hydrochloride salt form of thioridazine, a piperidine phenothiazine derivative and a dopamine antagonist with antipsychotic property. Thioridazine hydrochloride binds to mesolimbic postsynaptic dopamine receptor D2, thereby decreasing dopamine activity leading to decreased psychotic effects, such as hallucinations and delusions. In addition, this agent binds to serotonin 5-HT2 receptors, resulting in decreased serotonin activity. A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA. See also: Thioridazine (has active moiety). |
| Molecular Formula |
C21H26N2S2.HCL
|
|---|---|
| Molecular Weight |
407.03
|
| Exact Mass |
406.13
|
| CAS # |
130-61-0
|
| Related CAS # |
Thioridazine;50-52-2
|
| PubChem CID |
66062
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
515.7ºC at 760 mmHg
|
| Melting Point |
158-1600C
|
| Flash Point |
265.7ºC
|
| Vapour Pressure |
9.65E-11mmHg at 25°C
|
| LogP |
6.69
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
26
|
| Complexity |
432
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
NZFNXWQNBYZDAQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H26N2S2.ClH/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23;/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3;1H
|
| Chemical Name |
10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~245.68 mM)
DMSO : ≥ 45 mg/mL (~110.55 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.11 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.11 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.11 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 12.5 mg/mL (30.71 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4568 mL | 12.2841 mL | 24.5682 mL | |
| 5 mM | 0.4914 mL | 2.4568 mL | 4.9136 mL | |
| 10 mM | 0.2457 mL | 1.2284 mL | 2.4568 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
